Variables Affecting Reconstitution Time of Dry Powder for Injection - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Variables Affecting Reconstitution Time of Dry Powder for Injection
The authors describe the factors affecting reconstitution time of dry powder for injection and classifies them as intrinsic and extrinsic parameters.


Pharmaceutical Technology


References

1. "‹1› Injections" in USP 29–NF 24 (United States Pharmacopeial Convention, Rockville, MD, 2006), pp. 2455–2458.

2. International Conference on Harmonization, Q6A: Specifications: Test Procedures and Acceptance Criteria For New Drug Substances and New Drug Products:Chemical Substances (ICH, Geneva, Switzerland, 2003).

3. "Amifostine for Injection" in USP 29–NF 24 (United States Pharmacopeial Convention, Rockville, MD, 2006), p. 126.

4. "Haemosolvate Factor VIII (Powder for Injection)," package insert (Pinetown, South Africa), http://www.home.intekom.com/pharm/nbi/viii1000.html, accessed May 11, 2007.

5. S. Redkar and P. Phiasivongsa, "Salts of 5-Azacytidine," US Patent 2006/0063735 A1 (2006).

6. A.A. Noyes and W.R. Whitney, "The Rate of Solution of Solid Substances in Their Own Solutions," J. Am. Chem. Soc. 19 (12), 930–934 (1897).

7. M. Melgardt, "Influence of Agglomeration of Cohesive Particles on the Dissolution Behaviour of Furosemide Powder," Int. J. Pharm. 136, 175–179 (1996).

8. P.K. Hla and S. Hogekamp, "Wetting Behaviour of Instantized Cocoa Beverage Powders," Int. J. Food Sci. Technol. 34, 335–342 (1999).

9. W. Wu and G.H. Nancollas, "Determination of Interfacial Tension from Crystallization and Dissolution Data: A Comparison with Other Methods," Adv. Colloid Interface Sci. 79 (2–3), 229–279 (1999).

10. H.E. Bruce, "Composition of Matter Comprising a Lyophilized Preparation of a Penicillin Derivative," US Patent 4477452 (1984).

11. L. Moscou and S. Lub, "Practical Use of Mercury Porosimetry in the Study of Porous Solids," Powder Technol. 29 (1), 45–52 (1981).

12. S. Westermarck et al., "Mercury Porosimetry of Pharmaceutical Powders and Granules," J. Porous Mater. 5 (1), 77–86 (1998).

13. P.J. Dees and J. Polderman, "Mercury Porosimetry in Pharmaceutical Technology," Powder Technol. 29 (1), 187–197 (1981).

14. S. Westermarck et al., "Pore Structure and Surface Area of Mannitol Powder, Granules and Tablets Determined with Mercury Porosimetry and Nitrogen Adsorption," Eur. J. Pharm. Biopharm. 46 (1), 61–68 (1998).

15. S. Brunauer et al., "Adsorption of Gases in Multimolecular Layers," J. Am. Chem. Soc. 60 (2), 309–319 (1938).

16. L. Farber et al., "Use of X-ray Tomography to Study the Porosity and Morphology of Granules," Powder Technol. 132 (1), 57–63 (2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here